McKesson Buys Maryland CRO Precision Medicine Group in $2.25 Billion Deal
Morgan Stanley calls McKesson’s $2.25B Precision Medicine buy a logical CRO addition unlocking a $25B oncology market.
/ 1648 items
#XY↓
Kura Oncology Chairman and CEO Acquires Additional Company Shares
Kura Oncology CEO Troy Wilson purchased 100,000 shares at a $12.39 weighted average price. This follows a similar buy one week earlier, increasing his direct and trust holdings.
Agomab: Piper Sandler Sees 368% Upside on Ontunisertib for Fibrostenotic Crohn’s
Agomab trades at a deep discount to Sarepta and Abivax. Piper Sandler starts at Overweight with $60 PT.
Apnimed Stock Jumps After BofA and Cantor Kick Off Coverage with Big Upside Targets
BofA and Cantor Fitzgerald initiate coverage on Apnimed with Buy and Overweight ratings for Oxnimbi, its oral therapy for obstructive sleep apnea.
Jazz Pharma Stock Hits All-Time High After FDA Approves Ziihera for Stomach Cancer
The FDA has approved Jazz's Ziihera as a first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma, establishing a new standard of care.
Summit’s Ivonescimab Delivers First Major PFS Win in EGFR-Mutated Lung Cancer After TKI Failure
HARMONi Phase 3 results in The Lancet Oncology show ivonescimab + chemo cuts progression risk nearly in half for post-TKI EGFR-mutated NSCLC.